Anaplastic lymphoma kinase gene rearrangement in non-small-cell lung cancer in a Brazilian population

Clinics

Volumn 67, Issue 7, 2012, Pages 845-847

  Lopes, Lisandro F ^a   Bacchi, Carlos E ^a  

^a Consultoria em Patologia ^*  (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; PROTEIN TYROSINE KINASE;

ADULT; AGED; ARTICLE; BRAZIL; ENZYMOLOGY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BRAZIL; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE REARRANGEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84867072440     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2012(07)23     Document Type: Article

References (41)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212-36, http://dx.doi.org/10.3322/caac.20121.
2. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-smallcell lung cancer. Nature. 2007;448(7153):561-6, http://dx.doi.org/10.1038/nature05945.
3. Soda M, Takada S, Takeuchi K, Choi YL, Enomoto M, Ueno T, et al. A mousemodel forEML4-ALK-positive lungcancer. ProcNatlAcadSciUS A. 2008;105(50):19893-7, http://dx.doi.org/10.1073/pnas.0805381105.
4. Wong DW, Leung EL, So KK, Tam IY, Sihoe AD, Cheng LC, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer. 2009;115(8):1723-33, http://dx.doi.org/10.1002/cncr.24181.
5. Inamura K, Takeuchi K, Togashi Y, Hatano S, Ninomiya H, Motoi N, et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol. 2009;22(4):508-15, http://dx.doi.org/10.1038/modpathol.2009.2.
6. Boland JM, Erdogan S, Vasmatzis G, Yang P, Tillmans LS, Johnson MR, et al. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in nonsmall-cell lung carcinomas. Hum Pathol. 2009;40(8):1152-8, http://dx.doi.org/10.1016/j.humpath.2009.01.012.
7. Takeuchi K, Choi YL, Soda M, Inamura K, Togashi Y, Hatano S, et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res. 2008;14(20):6618-24, http://dx.doi.org/10.1158/1078-0432.CCR-08-1018.
8. Solomon B, Varella-Garcia M, Camidge DR. ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small-cell lung cancer. J Thorac Oncol. 2009;4(12):1450-4, http://dx.doi.org/10.1097/JTO.0b013e3181c4dedb.
9. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363(18):1693-703, http://dx.doi.org/10.1056/NEJMoa1006448.
10. Mino-Kenudson M, Mark EJ. Reflex testing for epidermal growth factor receptor mutation and anaplastic lymphoma kinase fluorescence in situ hybridization in non-small-cell lung cancer. Arch Pathol Lab Med. 2011;135(5):655-64.
11. Paik JH, Choi CM, Kim H, Jang SJ, Choe G, Kim DK, et al. Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALKrearranged adenocarcinoma. Lung Cancer. 2012;76(3):403-9, http://dx.doi.org/10.1016/j.lungcan.2011.11.008.
12. Li C, Fang R, Sun Y, Han X, Li F, Gao B, et al. Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers. PLoS One. 2011;6(11):e28204, http://dx.doi.org/10.1371/journal.pone.0028204.
13. Kim H, Yoo SB, Choe JY, Paik JH, Xu X, Nitta H, et al. Detection of ALK gene rearrangement in non-small-cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression. J Thorac Oncol. 2011;6(8):1359-66, http://dx.doi.org/10.1097/JTO.0b013e31821cfc73.
14. Paik JH, Choe G, Kim H, Choe JY, Lee HJ, Lee CT, et al. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small-cell lung cancer: correlation with fluorescence in situ hybridization. J Thorac Oncol. 2011;6(3):466-72, http://dx.doi.org/10.1097/JTO.0b013e31820b82e8.
15. Sun Y, Ren Y, Fang Z, Li C, Fang R, Gao B, et al. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol. 2010;28(30):4616-20, http://dx.doi.org/10.1200/JCO.2010.29.6038.
16. Takahashi T, Sonobe M, Kobayashi M, Yoshizawa A, Menju T, Nakayama E, et al. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol. 2010;17(3):889-97, http://dx.doi.org/10.1245/s10434-009-0808-7.
17. Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, Barletta JA, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res. 2009;15(16):5216-23, http://dx.doi.org/10.1158/1078-0432.CCR-09-0802.
18. Solomon B, Shaw AT. Are Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small-cell lung Cancer Prognostic, Predictive, or Both? J Thorac Oncol. 2012;7(1):5-7, http://dx.doi.org/10.1097/JTO. 0b013e31823f1289.
19. Sakairi Y, Nakajima T, Yasufuku K, Ikebe D, Kageyama H, Soda M, et al. EML4-ALK fusion gene assessment using metastatic lymph node samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration. Clin Cancer Res. 2010;16(20):4938-45, http://dx.doi.org/10.1158/1078-0432.CCR-10-0099.
20. Yoshida A, Tsuta K, Nakamura H, Kohno T, Takahashi F, Asamura H, et al. Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am J Surg Pathol. 2011;35(8):1226-34, http://dx.doi.org/10.1097/PAS.0b013e3182233e06.
21. Zhang X, Zhang S, Yang X, Yang J, Zhou Q, Yin L, et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer. 2010;13(9):188, http://dx.doi.org/10.1186/1476-4598-9-188.
22. Sasaki T, Rodig SJ, Chirieac LR, Janne PA. The biology and treatment of EML4-ALK non-small-cell lung cancer. Eur J Cancer. 2010;46(10):1773-80, http://dx.doi.org/10.1016/j.ejca.2010.04.002.
23. Yang P, Kulig K, Boland JM, Erickson-Johnson MR, Oliveira AM, Wampfler J, et al. Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma. J Thorac Oncol. 2012;7(1):90-7, http://dx.doi.org/10.1097/JTO.0b013e31823c5c32.
24. Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res. 2008;14(13):4275-83, http://dx.doi.org/10.1158/1078-0432.CCR-08-0168.
25. Hallberg B, Palmer RH. Crizotinib--latest champion in the cancer wars? N Engl J Med. 2010;363(18):1760-2, http://dx.doi.org/10.1056/NEJMe1010404.
26. Trial watch: success for crizotinib in ALK-driven cancer. Nat Rev Drug Discov. 2010;9(12):908.
27. Ou SH. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small-cell lung cancer and beyond. Drug Des Devel Ther. 2011;5:471-85, http://dx.doi.org/10.2147/DDDT.S19045.
28. Shaw AT, Solomon B, Kenudson MM. Crizotinib and testing for ALK. J Natl Compr Canc Netw, 2011;9(12):1335-41.
29. Ou SH, Bazhenova L, Camidge DR, Solomon BJ, Herman J, Kain T, et al. Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small-cell lung cancer. J Thorac Oncol. 2010;5(12): 2044-6, http://dx.doi.org/10.1097/JTO.0b013e318200f9ff.
30. Freeman A, Geddes N, Munson P, Joseph J, Ramani P, Sandison A, et al. Anaplastic lymphoma kinase (ALK 1) staining and molecular analysis in inflammatory myofibroblastic tumours of the bladder: a preliminary clinicopathological study of nine cases and review of the literature. Mod Pathol. 2004;17(7):765-71, http://dx.doi.org/10.1038/modpathol.3800078.
31. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27(26):4247-53, http://dx.doi.org/10.1200/JCO.2009.22.6993.
32. Martelli MP, Sozzi G, Hernandez L, Pettirossi V, Navarro A, Conte D, et al. EML4-ALK rearrangement in non-small-cell lung cancer and nontumor lung tissues. Am J Pathol. 2009;174(2):661-70, http://dx.doi.org/10.2353/ajpath.2009.080755.
33. Yi ES, Boland JM, Maleszewski JJ, Roden AC, Oliveira AM, Aubry MC, et al. Correlation of IHC and FISH for ALK gene rearrangement in nonsmall-cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol. 2011;6(3):459-65, http://dx.doi.org/10.1097/JTO.0b013e318209edb9.
34. McLeer-Florin A, Moro-Sibilot D, Melis A, Salameire D, Lefebvre C, Ceccaldi F, et al. Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: A French study. J Thorac Oncol. 2012;7(2):348-54, http://dx.doi.org/10.1097/JTO.0b013e3182381535.
35. Hofman P, Ilie M, Hofman V, Roux S, Valent A, Bernheim A, et al. Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma. Ann Oncol. 2011 Nov 18. [Epub ahead of print]
36. McLeer-Florin A, Moro-Sibilot D, Melis A, Salameire D, Lefebvre C, Ceccaldi F, de Fraipont F, Brambilla E, Lantuejoul S. Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study. J Thorac Oncol. 2012;7(2):348-54, http://dx.doi.org/10.1097/JTO.0b013e3182381535.
37. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6(2):244-85, http://dx.doi.org/10.1097/JTO.0b013e318206a221.
38. Tsao AS, Tang XM, Sabloff B, Xiao L, Shigematsu H, Roth J, et al. Clinicopathologic characteristics of the EGFR gene mutation in nonsmall-cell lung cancer. J Thorac Oncol. 2006;1(3):231-9.
39. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97(5):339-46, http://dx.doi.org/10.1093/jnci/dji055.
40. Riely GJ, Marks J, Pao W. KRAS mutations in non-small-cell lung cancer. Proc Am Thorac Soc. 2009;6(2):201-5, http://dx.doi.org/10.1513/pats.200809-107LC.
41. Inamura K, Ninomiya H, Ishikawa Y, Matsubara O. Is the epidermal growth factor receptor status in lung cancers reflected in clinicopathologic features? Arch Pathol Lab Med. 2010;134(1):66-72.